Cover Image
市場調查報告書

日本的血流儲備分數 (FFR) 檢測用導管導引線市場

Japan Market Report for Fractional Flow Reserve Guidewires 2018 - MedCore

出版商 iData Research Inc. 商品編碼 616040
出版日期 內容資訊 英文 672 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
日本的血流儲備分數 (FFR) 檢測用導管導引線市場 Japan Market Report for Fractional Flow Reserve Guidewires 2018 - MedCore
出版日期: 2017年10月01日 內容資訊: 英文 672 Pages
簡介

本報告提供日本的血流儲備分數 (FFR) 檢測用導管導引線市場相關調查分析,提供疾病概要,產品評估,市場分析相關的系統性資訊。

摘要整理

日本的介入心臟病學市場概要

競爭分析

市場趨勢

市場發展

對象市場

對象治療

版本履歷

第1章 調查手法

第2章 疾病概要

  • 基本結構
  • 疾病的治療和診斷
  • 患者的人口動態

第3章 產品評估

  • 產品系列
  • 法規問題和回收
  • 臨床實驗

第4章 血流儲備分數 (FFR) 檢測用導管導引線市場

  • 簡介
  • 市場分析與預測
  • 促進因素及阻礙因素
    • 推動市場要素
    • 市場阻礙因素
  • 競爭市場佔有率分析

簡稱

附錄

目錄
Product Code: iDATA_JPIC18_MC_FFR

Fractional flow reserve (FFR) is a guidewire-based procedure that can accurately measure blood pressure and flow through a specific part of the coronary artery. FFR guidewires are inserted through a diagnostic catheter during a coronary angiogram. While FFR was still used in only a small percentage of angiography procedures, it is useful in assessing whether or not to perform angioplasty or stenting on "borderline" blockages. FFR provides data that is complementary to information from standard diagnostic guidewires and imaging systems.

General Report Contents:

  • Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
  • Market Drivers & Limiters for each chapter segment
  • Competitive Analysis for each chapter segment
  • Section on recent mergers & acquisitions

The market for FFR guidewires will grow significantly faster than the rest of the market due to positive clinical results when used for assisting stent placement and increasing ease of use. Recent development from St. Jude Medical (now Abbott) has demonstrated improved outcomes with complex anatomies, allowing physicians the option to use FFR guidewires in a wider range of patients. Furthermore, the number of competitors is expected to increase which will lead to more research and development in the area.

Table of Contents

TABLE OF CONTENTS I

LIST OF FIGURES XXI

LIST OF CHARTS XXIX

EXECUTIVE SUMMARY 1

JAPAN INTERVENTIONAL CARDIOLOGY MARKET OVERVIEW 1

COMPETITIVE ANALYSIS 4

MARKET TRENDS 7

MARKET DEVELOPMENTS 9

MARKETS INCLUDED 10

PROCEDURES INCLUDED 11

VERSION HISTORY 11

RESEARCH METHODOLOGY 12

    • Step 1: Project Initiation & Team Selection 12
    • Step 2: Prepare Data Systems and Perform Secondary Research 15
    • Step 3: Preparation for Interviews & Questionnaire Design 17
    • Step 4: Performing Primary Research 18
    • Step 5: Research Analysis: Establishing Baseline Estimates 20
    • Step 6: Market Forecasts and Analysis 21
    • Step 7: Identify Strategic Opportunities 23
    • Step 8: Final Review and Market Release 24
    • Step 9: Customer Feedback and Market Monitoring 25

DISEASE OVERVIEW 26

  • 2.1 BASIC ANATOMY 26
  • 2.2 DISEASE TREATMENTS AND DIAGNOSTICS 28
    • 2.2.1 General Diagnostics 28
    • 2.2.2 Coronary Artery Disease (CAD) 28
    • 2.2.3 Myocardial Infarction (MI) 29
    • 2.2.4 Angina Pectoris 30
  • 2.3 PATIENT DEMOGRAPHICS 31
    • 2.3.1 General Statistics 31

PRODUCT ASSESSMENT 33

  • 3.1 PRODUCT PORTFOLIOS 33
    • 3.1.1 Coronary Guidewires Market 33
      • 3.1.1.1 Interventional Coronary Guidewires 33
      • 3.1.1.2 Fractional Flow Reserve (FFR) Guidewire 34
  • 3.2 REGULATORY ISSUES AND RECALLS 39
    • 3.2.1 Boston Scientific 39
      • 3.2.1.1 Coronary Stent 39
      • 3.2.1.2 PTCA Balloon Catheter 39
      • 3.2.1.3 Interventional Coronary Catheters and Guidewires 40
      • 3.2.1.4 Coronary Embolic Protection Device 41
    • 3.2.2 Cardinal Health 41
      • 3.2.2.1 Coronary Vascular Closure Device 41
    • 3.2.3 Cook Medical 42
      • 3.2.3.1 Coronary Stent 42
      • 3.2.3.2 Interventional Coronary Catheters and Guidewires 42
    • 3.2.4 Cordis (Cardinal Health) 43
      • 3.2.4.1 PTCA Balloon Catheter/Dilation Catheters 43
      • 3.2.4.2 Interventional Coronary Catheters and Guidewires 44
    • 3.2.5 Medtronic 45
      • 3.2.5.1 Coronary Stent 45
      • 3.2.5.2 PTCA Balloon and Dilation Catheters 45
      • 3.2.5.3 Interventional Coronary Catheters and Guidewires 46
    • 3.2.6 Merit Medical Systems 49
      • 3.2.6.1 Interventional Coronary Catheters and Guidewires 49
      • 3.2.6.2 Coronary Introducer Sheath 51
    • 3.2.7 Spectranetics 52
      • 3.2.7.1 Coronary Atherectomy Device 52
    • 3.2.8 St. Jude Medical (Abbott Laboratories) 53
      • 3.2.8.1 Coronary Vascular Closure Device 53
      • 3.2.8.2 Interventional Coronary Catheters and Guidewires 53
    • 3.2.9 Vascular Solutions (Teleflex) 54
      • 3.2.9.1 Interventional Coronary Catheters and Guidewires 54
    • 3.2.10 Volcano Therapeutics (Philips Volcano) 55
      • 3.2.10.1 Interventional Coronary Catheters and Guidewires 55
      • 3.2.10.2 Intravascular Ultrasound (IVUS) Catheter 55
    • 3.2.11 Other Companies 56
      • 3.2.11.1 Coronary Stent and other Vascular Stents 56
      • 3.2.11.2 PTCA balloon catheter 56
      • 3.2.11.3 Interventional Coronary Catheters and Guidewires 57
      • 3.2.11.4 Coronary Atherectomy Device 59
      • 3.2.11.5 Coronary Introducer Sheath 60
      • 3.2.11.6 Intravascular Ultrasound (IVUS) Catheter 60
  • 3.3 CLINICAL TRIALS 61
    • 3.3.1 Abbott Laboratories 61
      • 3.3.1.1 Coronary Stent 61
    • 3.3.2 Asahi Intecc 70
      • 3.3.2.1 Interventional Coronary Catheters and Guidewires 70
    • 3.3.3 B. Braun 71
      • 3.3.3.1 Coronary Stent 71
      • 3.3.3.2 PTCA balloon catheter 72
    • 3.3.4 Biosensors 76
      • 3.3.4.1 Coronary Stent 76
    • 3.3.5 Biotronik 78
      • 3.3.5.1 Coronary Stent 78
      • 3.3.5.2 PTCA balloon catheter 81
    • 3.3.6 Boston Scientific 82
      • 3.3.6.1 Coronary Stent 82
      • 3.3.6.3 PTCA balloon catheter 85
      • 3.3.6.4 Coronary Embolic Protection Device 85
    • 3.3.7 Medtronic 86
      • 3.3.7.1 Coronary Stent 86
      • 3.3.7.2 Interventional Coronary Catheters and Guidewires 89
      • 3.3.7.3 Coronary Embolic Protection Device 90
    • 3.3.8 St. Jude Medical (Abbott Laboratories) 91
      • 3.3.8.1 Interventional Coronary Catheters and Guidewires 91
      • 3.3.8.2 Intravascular Ultrasound (IVUS) Catheter 91
      • 3.3.8.3 Optical Coherence Tomography Catheter 92
      • 3.3.8.4 Fractional Flow Reverse (FFR) Catheter 92
    • 3.3.9 Terumo Interventional Systems (TIS) 93
      • 3.3.9.1 Interventional Coronary Catheters and Guidewires 93
      • 3.3.9.2 Coronary Embolic Protection Device 93
    • 3.3.10 Other Companies 94
      • 3.3.10.1 Coronary Stent 94
      • 3.3.10.2 PTCA balloon catheter 106
      • 3.3.10.3 Interventional Coronary Catheters and Guidewires 107
      • 3.3.10.4 Coronary Embolic Protection Device 110
      • 3.3.10.5 Coronary Chronic Total Occlusion Crosser CTO 111
      • 3.3.10.7 Fractional Flow Reserve (FFR) Guidewire 112
      • 3.3.10.8 Optical Coherence Tomography (OCT) Guidewire 112

FRACTIONAL FLOW RESERVE GUIDEWIRE MARKET 114

  • 4.1 INTRODUCTION 114
  • 4.2 MARKET ANALYSIS AND FORECAST 114
  • 4.3 DRIVERS AND LIMITERS 117
    • 4.3.1 Market Drivers 117
    • 4.3.2 Market Limiters 117
  • 4.4 COMPETITIVE MARKET SHARE ANALYSIS 119

ABBREVIATIONS 122

APPENDIX: COMPANY PRESS RELEASES 124

LIST OF CHARTS

  • Chart 1 1: Interventional Cardiology Market by Segment, Japan, 2014 - 2024 3
  • Chart 1 2: Interventional Cardiology Market Overview, Japan, 2017 & 2024 3
  • Chart 4 1: Coronary Pressure and Flow Guidewire Market, Japan, 2014 - 2024 116
  • Chart 4 2: Leading Competitors, Coronary Pressure and Flow Guidewire Market, Japan, 2017 121

LIST OF FIGURES

  • Figure 1 1: Interventional Cardiology Market Share Ranking by Segment, Japan, 2017 (1 of 2) 4
  • Figure 1 2: Interventional Cardiology Market Share Ranking by Segment, Japan, 2017 (2 of 2) 5
  • Figure 1 3: Companies Researched in this Report, Japan, 2017 6
  • Figure 1 4: Factors Impacting the Interventional Cardiology Market by Segment, Japan (1 of 2) 7
  • Figure 1 5: Factors Impacting the Interventional Cardiology Market by Segment, Japan (2 of 2) 8
  • Figure 1 6: Recent Events in the Interventional Cardiology Market, Japan, 2014 - 2017 9
  • Figure 1 7: Interventional Cardiology Markets Covered, Japan, 2017 10
  • Figure 1 8: Interventional Cardiology Procedures Covered, Japan, 2017 11
  • Figure 1 9: Version History 11
  • Figure 3 1: Coronary Guidewire Products by Company (1 of 3) 36
  • Figure 3 2: Coronary Guidewire Products by Company (2 of 3) 37
  • Figure 3 3: Coronary Guidewire Products by Company (3 of 3) 38
  • Figure 3 4: Class 1 Device Recall Boston Scientific Fetch 2 Aspiration Catheter 39
  • Figure 3 5: Class 2 Device Recall Boston Scientific, Small Peripheral Cutting BalloonTM 39
  • Figure 3 6: Class 2 Device Recall Boston Scientific, FlextomeTM Cutting BalloonTM 39
  • Figure 3 7: Class 2 Device Recall Boston Scientific ACUITY Pro Coronary Sinus Guide Catheter 40
  • Figure 3 8: Class 1 Device Recall Boston Scientific Fetch 2 Aspiration Catheter 40
  • Figure 3 9: Class 2 Device Recall Boston Scientific, FlextomeTM Cutting BalloonTM 40
  • Figure 3 10: Class 1 Device Recall RotaWire Elite and sireClip Torquer, Guidewire and Guidewire Manipulation Device, Floppy 41
  • Figure 3 11: Class 2 Device Recall MynxGrip Vascular Closure Device 41
  • Figure 3 12: Class 2 Device Recall Zilver 518RX Vascular Stent 42
  • Figure 3 13: Class 2 Device Recall Zilver 518 Vascular Self Expanding Stent 42
  • Figure 3 14: Class 2 Device Recall White Lumax Guiding Coaxial Catheter 42
  • Figure 3 15: Class 2 Device Recall Cordis POWERFLEX PRO PTA Dilatation Catheter 43
  • Figure 3 16: Class 2 Device Recall EMPIRA ? NC RX PTCA Dilatation Catheter 43
  • Figure 3 17: Class 2 Device Recall Cordis EMPIRA RX PTCA Dilatation Catheter 43
  • Figure 3 18: Class 2 Device Recall Cordis ADROIT 6F Guiding Catheter 44
  • Figure 3 19: Class 2 Device Recall Resolute Integrity Zotarolimuseluting Coronary Stent 45
  • Figure 3 20: Class 2 Device Recall PowerCross .018 OTW PTA Dilation Catheter 45
  • Figure 3 21: Class 2 Device Recall Ev3, Inc. (Medtronic) 45
  • Figure 3 22: Class 2 Device Recall NC Sprinter; Rapid Exchange Balloon Dilatation Catheter 46
  • Figure 3 23: Class 2 Device Recall Medtronic Launcher Coronary Guide Catheter 46
  • Figure 3 24: Class 2 Device Recall Launcher Coronary Guiding Catheter 46
  • Figure 3 25: Class 1 Device Recall ZINGER Steerable Guidewire 46
  • Figure 3 26: Class 1 Device Recall Cougar Nitinol Workhorse Guidewire 47
  • Figure 3 27: Class 1 Device Recall COUGAR Steerable Guidewire 47
  • Figure 3 28: Class 1 Device Recall THUNDER Steerable Guidewire 47
  • Figure 3 29: Class 1 Device Recall ProVia CROSSING GUIDEWIRE 47
  • Figure 3 30: Class 1 Device Recall ATTAIN HYBRID Guide Wire 48
  • Figure 3 31: Class 2 Device Recall Medtronic Zuma Guide Catheter 48
  • Figure 3 32: Class 2 Device Recall Merit Maestro Microcatheter 49
  • Figure 3 33: Class 2 Device Recall Merit Laureate Hydrophilic Guide Wire 49
  • Figure 3 34: Class 2 Device Recall Maestro Microcatheter, Merit Medical System 49
  • Figure 3 35: Class 2 Device Recall Performa Cardiac Multipack Catheter 50
  • Figure 3 36: Class 2 Device Recall Hydrophylic guidewire 50
  • Figure 3 37: Class 2 Device Recall PreludeEASE 51
  • Figure 3 38: Class 2 Device Recall Prelude Pro Sheath Introducter 51
  • Figure 3 39: Class 2 Device Recall Turbo Elite Atherectomy Catheter 52
  • Figure 3 40: Class 2 Device Recall ELCA Coronary Atherectomy Catheter 52
  • Figure 3 41: Class 2 Device Recall Vascular closure device 53
  • Figure 3 42: Class 3 Device Recall FastCath" Transseptal Guiding Introducer 53
  • Figure 3 43: Class 1 Device Recall TwinPass Dual Access Catheter 54
  • Figure 3 44: Class 2 Device Recall Percutaneous Catheter 54
  • Figure 3 45: Class 2 Device Recall Prestige Plus Wire 55
  • Figure 3 46: Class 2 Device Recall Volcano s5, s5i, CORE and CORE Mobile systems 55
  • Figure 3 47: Class 2 Device Recall Intravascular Ultrasound System 55
  • Figure 3 48: Class 2 Device Recall FLAIR Endovascular Stent Graft, Bard Peripheral Vascular 56
  • Figure 3 49: Class 1 Device Recall LifeStent Solo Vascular Stent, Bard Peripheral Vascular 56
  • Figure 3 50: Class 2 Device Recall PTA Balloon Dilatation Catheters 56
  • Figure 3 51: Class 2 Device Recall VIA 27 Microcatheters, Sequent Medical Inc. 57
  • Figure 3 52: Class 2 Device Recall Coronary Artery Perfusion Cannula with Balloon, Sorin Group USA, Inc. 57
  • Figure 3 53: Class 2 Device Recall Aortic Arch Cannula, Sorin Group USA, Inc. 57
  • Figure 3 54: Class 2 Device Recall Mallinckrodt Launcher Guiding Catheter, Stryker Sustainability Solutions 57
  • Figure 3 55: Class 2 Device Recall Distal Access Catheter (DAC), Concentric Medical Inc 58
  • Figure 3 56: Class 2 Device Recall Distal Access Catheter 58
  • Figure 3 57: Class 2 Device Recall Proplege Coronary Sinus Catheter, Edwards Lifesciences, LLC 58
  • Figure 3 58: Class 2 Device Recall Turbo Elite, ELCA Atherectomy Catheter, Spectranetics Corporation 59
  • Figure 3 59: Class 1 Device Recall Diamondback 360 Coronary Orbital Artherctomy System, Cardiovascular Systems, Inc. 59
  • Figure 3 60: Class 3 Device Recall Diamondback 360 Coronary Orbital Atherectomy System 59
  • Figure 3 61: Class 2 Device Recall VIA 27 Microcatheters, Sequent Medical Inc 60
  • Figure 3 62: Class 1 Device Recall Halo One ThinWalled Guiding Sheath, Bard Peripheral Vascular 60
  • Figure 3 63: Class 2 Device Recall SOUNDSTAR eco Catheter, Biosense Webster, Inc. 60
  • Figure 3 64: XIENCE Xpedition/Alpine in Routine Clinical Practice (IRIS XPEDITION) 61
  • Figure 3 65: Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC) 61
  • Figure 3 66: Trial of MiStent Compared to Xience in Japan (DESSOLVEJ) 62
  • Figure 3 67: Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis (HOST-ALPINE) 62
  • Figure 3 68: XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS) 63
  • Figure 3 69: Absorb IV Randomized Controlled Trial 63
  • Figure 3 70: Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA) 64
  • Figure 3 71: Xience Versus Synergy in Left Main PCI (IDEAL-LM) 64
  • Figure 3 72: Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent (TALENT) 65
  • Figure 3 73: XIENCE PRIME SV Everolimus Eluting Coronary Stent Post Marketing Surveillance (XIENCE PRIME SV PMS) 65
  • Figure 3 74: XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study (XP China SAS) 66
  • Figure 3 75: A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT) (ABSORB CHINA) 66
  • Figure 3 76: AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population (ABSORB JAPAN) 67
  • Figure 3 77: XIENCE PRIME Japan Post-Marketing Surveillance (PMS) 67
  • Figure 3 78: EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent, Performance, and Technique in Chronic Total Occlusions 68
  • Figure 3 79: Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE (PATRIOT) 68
  • Figure 3 80: Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction (APPOSITION V) 69
  • Figure 3 81: Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis (RESTORE) 69
  • Figure 3 82: The Asahi Intecc PTCA Chronic Total Occlusion Study (CTO-PCI) 70
  • Figure 3 83: Optilene® Suture for Coronary Artery Bypass Graft Surgery (OPTICABG) 71
  • Figure 3 84: Treatment of Coronary Artery Disease (CAD) With Bare Metal Stent (BMS) Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent 71
  • Figure 3 85: Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients (PEPCAD IV) 72
  • Figure 3 86: Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR) 72
  • Figure 3 87: Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions (PEPCAD V) 73
  • Figure 3 88: The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations (PEPCAD-BIF) 73
  • Figure 3 89: INDICOR The Paclitaxel-Eluting PTCA-Balloon Catheter in Combination With a Cobalt-Chromium Stent (INDICOR) 74
  • Figure 3 90: A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent (PEPCAD) 74
  • Figure 3 91: The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions (PEPCAD-CTO) 75
  • Figure 3 92: PEPCAD I. The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel 75
  • Figure 3 93: LEADERS FREE II: BioFreedom™ Pivotal Study 76
  • Figure 3 94: BioFreedom US IDE Feasibility Trial 76
  • Figure 3 95: A Randomized Clinical Evaluation of the BioFreedom™ Stent (Leaders Free) 77
  • Figure 3 96: Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease (ABSORB-LONG) 78
  • Figure 3 97: BIOTRONIK Orsiro Pre-Marketing Registration (BIOFLOW-VI) 78
  • Figure 3 98: Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions 79
  • Figure 3 99: BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite 79
  • Figure 3 100: BIOHELIX-I Bare Metal Stent Study (BIOHELIX-I) 80
  • Figure 3 101: BIOFLOW III Asia Registry 80
  • Figure 3 102: BIOFLOW-III Israel Satellite Registry 80
  • Figure 3 103: Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT (REMEDEE-OCT) 81
  • Figure 3 104: Drug Eluting Pantera Lux Catheter Registry 81
  • Figure 3 105: Post-Approval Study of PROMUS Element™ in China (PEChina) 82
  • Figure 3 106: EVOLVE China Clinical Trial (EVOLVE China) 82
  • Figure 3 107: EVOLVE Short DAPT Study 83
  • Figure 3 108: PROMUS Element Plus US Post-Approval Study 83
  • Figure 3 109: The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s) 84
  • Figure 3 110: SYNERGY China: Assess SYNERGY Stent in China 84
  • Figure 3 111: Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter 85
  • Figure 3 112: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation 85
  • Figure 3 113: Safety and Efficacy of the CRE8 Stent for the Treatment of De Novo Coronary Artery Lesions 86
  • Figure 3 114: RESOLUTE ONYX Post-Approval Study (ONYX PAS) 86
  • Figure 3 115: Medtronic RevElution Trial (RevElution) 87
  • Figure 3 116: The European Bifurcation Club Left Main Study (EBC MAIN) 87
  • Figure 3 117: Medtronic Resolute Onyx 2.0 mm Clinical Study 87
  • Figure 3 118: Medtronic Resolute Onyx Core (2.25 mm - 4.0 mm) Clinical Study 88
  • Figure 3 119: Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY) 88
  • Figure 3 120: An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (RI-US) 89
  • Figure 3 121: Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study (JUDGE) 89
  • Figure 3 122: Atrial Fibrillation Detected by Continuous ECG Monitoring (LOOP) 90
  • Figure 3 123: Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia (STAR-VT) 91
  • Figure 3 124: ILUMIEN III: OPTIMIZE PCI 91
  • Figure 3 125: ILUMIEN III: OPTIMIZE PCI 92
  • Figure 3 126: Portuguese Study on The Evaluation of FFR Guided Treatment of Coronary Disease (POST-IT) 92
  • Figure 3 127: Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study (JUDGE) 93
  • Figure 3 128: Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis 93
  • Figure 3 129: Firehawk™ Coronary Stent System in the Treatment of Total Coronary Artery Occlusion Lesion(s) 94
  • Figure 3 130: Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III) 94
  • Figure 3 131: Trial of MiStent Compared to Xience in Japan (DESSOLVEJ) 95
  • Figure 3 132: MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (JNIR) 95
  • Figure 3 133: Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation 96
  • Figure 3 134: BIONICS - Pharmacokinetics (PK) Trial (BIONICS) 96
  • Figure 3 135: Safety and Efficacy Study of the Amaranth Medical APTITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT II) 96
  • Figure 3 136: Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 ) 97
  • Figure 3 137: Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease (Firehawk_38) 97
  • Figure 3 138: Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (MEND II) 98
  • Figure 3 139: Safety and Efficacy Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT) 98
  • Figure 3 140: Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold (FANTOM II), Reva Medical 98
  • Figure 3 141: Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I) (FANTOM I), Reva Medical 99
  • Figure 3 142: NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial 99
  • Figure 3 143: A Prospective, Single-arm, Multi-centre, Observational, Real World Registry (Morpheus) 100
  • Figure 3 144: Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System (DIRECT II) 100
  • Figure 3 145: First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis 101
  • Figure 3 146: eTryton Left Main Registry Tryton Side Branch Stent® Tmt of Denovo CAD in LM and CFX Arteries (eTRYTONLM) 101
  • Figure 3 147: An Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study The BioMime™1 Trial (MeriT-II) 102
  • Figure 3 148: An BioMime Vs. Xience Randomised Control Clinical Study (meriT-V) 102
  • Figure 3 149: BIONICS Israel Trial 103
  • Figure 3 150: Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System 103
  • Figure 3 151: Sapphire II PRO US Clinical Study 104
  • Figure 3 152: Axetis Inert Coronary Stent System First In Man Clinical Investigation (AXETIS FIM) 104
  • Figure 3 153: Shockwave Coronary Rx Lithoplasty® Study (Disrupt CAD I) 104
  • Figure 3 154: Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation 105
  • Figure 3 155: Procedural Advantages of a Novel Drug-Eluting Coronary Stent 105
  • Figure 3 156: Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study 106
  • Figure 3 157: Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2) 106
  • Figure 3 158: Drug Eluting Balloon for Prevention of Constrictive Remodeling 107
  • Figure 3 159: Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent Restenosis 107
  • Figure 3 160: Real-time MRI Right Heart Catheterization Using Passive Catheters 108
  • Figure 3 161: A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions 108
  • Figure 3 162: Safety and Feasibility of Using a Single Transradial Guiding Catheter for Primary PCI (RAPID) 109
  • Figure 3 163: A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter 109
  • Figure 3 164: Performance of the CARDIOGARD Cannula (GECG) 110
  • Figure 3 165: DEFLECT II: A Study to Evaluate the Safety and Performance of the TriGuard™HDH in Patients Undergoing TAVR 110
  • Figure 3 166: Use of the GARDEX™ Embolic Protection Device During Percutaneous Coronary Interventions of Saphenous Vein Graft 111
  • Figure 3 167: Coherex WAVECREST I Left Atrial Appendage Occlusion Study 111
  • Figure 3 168: Trial to Compare FFR Measurement With a Non-Side-Hole Guide Catheter Vs. a Side-Hole Guide Catheter 112
  • Figure 3 169: Prospective Randomized Optical Coherence Tomography Oslo tRial (PROCTOR) 112
  • Figure 3 170: Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Stent Implantation (OCTACS) 113
  • Figure 4 1: Coronary Pressure and Flow Guidewire Market, Japan, 2014 - 2024 115
  • Figure 4 2: Drivers and Limiters, Coronary Pressure and Flow Guidewire Market, Japan, 2017 118
  • Figure 4 3: Leading Competitors, Coronary Pressure and Flow Guidewire Market, Japan, 2017 120
  • Figure 6 1: Press Release Summary 124
Back to Top